Published online Nov 26, 2018. doi: 10.4330/wjc.v10.i11.242
Peer-review started: August 9, 2018
First decision: August 24, 2018
Revised: September 8, 2018
Accepted: October 12, 2018
Article in press: October 12, 2018
Published online: November 26, 2018
Processing time: 109 Days and 0.5 Hours
The left atrial appendage (LAA) is a common site for intracardiac thrombus formation in patients with atrial fibrillation (AF). Surgical left atrial appendage occlusion (s-LAAO) during concomitant cardiac surgery has been evaluated as an effective treatment approach to reduce the risk of stroke and embolic events.
Percutaneous LAAO has been shown to be non-inferior compared with warfarin in reducing the risk of stroke and embolic events in two large randomized controlled trials, PROTECT-AF and PREVAIL. However, data regarding s-LAAO is conflicting and contrasting. So, we performed a systematic review and meta-analysis of all the studies published to date to evaluate if concomitant s-LAAO during cardiac surgery is safe and effective.
The purpose of this study is to evaluate the safety and efficacy of concomitant s-LAAO during cardiac surgery.
We searched five databases for studies comparing concomitant s-LAAO with no occlusion during cardiac surgery. We obtained a total of 12 studies for inclusion and performed a meta-analysis. The outcomes of interest were embolic events, stroke, all-cause mortality, AF, postoperative complications and reoperation for bleeding.
Concomitant s-LAAO during cardiac surgery was associated with lower risk of embolic events and stroke. This was evident in the AF predominant strata as well. There was no significant difference in the risk of all-cause mortality, AF, postoperative complications and reoperation for bleeding.
Our meta-analysis including all the studies published to date comparing concomitant s-LAAO against no occlusion during cardiac surgery supports the use of concomitant s-LAAO during cardiac surgeries. It was associated with lower risk of stroke and embolic events.
From this meta-analysis, it could be seen that concomitant s-LAAO during cardiac surgeries was associated with lower risk of stroke and embolic events compared with no occlusion. This association was prominent amongst the AF predominant strata as well. These beneficial effects could be seen due to the occlusion of LAA which is the source of 90% thrombi in non-valvular AF. Future randomized trials are needed to evaluate the long term benefits of s-LAAO.